Curculigoside improves osteogenesis of human amniotic fluid-derived stem cells

Stem Cells and Development

Volumn 23, Issue 2, 2014, Pages 146-154

  Liu, Meimei ^a   Li, Yan ^b   Yang, Shang Tian ^a  

^a The Ohio State University   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BETA CATENIN; CALCIUM; COLLAGEN TYPE 1; CURCULIGOSIDE; CYCLIN D1; GLYCOSIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; UNCLASSIFIED DRUG; WNT PROTEIN; BENZOIC ACID DERIVATIVE; COLLAGEN; GLUCOSIDE; TNFSF11 PROTEIN, HUMAN;

AMNION FLUID; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; UPREGULATION; WNT SIGNALING PATHWAY; BIOSYNTHESIS; CELL CULTURE; CHINESE MEDICINE; CURCULIGO; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; OSTEOCLAST; OSTEOPOROSIS;

ALKALINE PHOSPHATASE; AMNIOTIC FLUID; BENZOATES; BETA CATENIN; CALCIUM; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; CURCULIGO; CYCLIN D1; GLUCOSIDES; HUMANS; MEDICINE, CHINESE TRADITIONAL; OSTEOCLASTS; OSTEOGENESIS; OSTEOPONTIN; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; STEM CELLS; UP-REGULATION; WNT SIGNALING PATHWAY;

EID: 84891887659     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0261     Document Type: Article

References (43)

1. Rotella DP. (2002). Osteoporosis: challenges and new opportunities for therapy. Curr Opin Drug Discov Devel 5:477-486.
2. Harvey N, E Dennison and C Cooper. (2010). Osteoporosis: impact on health and economics. Nat Rev Rheumatol 6:99-105.
3. Cooper C. (1999). Epidemiology of osteoporosis. Osteoporos Int 9 Suppl 2:S2-S8.
4. Reginster JY and N Burlet. (2006). Osteoporosis: a still increasing prevalence. Bone 38:S4-S9.
5. Curtis JR and MM Safford. (2012). Management of osteoporosis among the elderly with other chronic medical conditions. Drugs Aging 29:549-564.
6. AAOS. (2008). Burden of Musculoskeletal Diseases in the United States: Prevalence, Societal and Economic Cost. American Academy of Orthopaedic Surgeons, Rosemont, IL.
7. Licata AA. (2005). Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 39:668-677.
8. Jiao L, DP Cao, LP Qin, T Han, QY Zhang, Z Zhu and F Yan. (2009). Antiosteoporotic activity of phenolic compounds from Curculigo orchioides. Phytomedicine 16:874-881.
9. De Coppi P, G Bartsch, Jr., MM Siddiqui, T Xu, CC Santos, L Perin, G Mostoslavsky, AC Serre, EY Snyder, et al. (2007). Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 25:100-106.
10. Yeh YC, HJ Wei, WY Lee, CL Yu, Y Chang, LW Hsu, MF Chung, MS Tsai, SM Hwang and HW Sung. (2010). Cellular cardiomyoplasty with human amniotic fluid stem cells: in vitro and in vivo studies. Tissue Eng Part A 16:1925-1936.
11. Liu Y, J Wu, Y Zhu and J Han. (2012). Therapeutic application of mesenchymal stem cells in bone and joint diseases. Clin Exp Med [Epub ahead of print]; DOI: 10.1007/s10238-012-0218-1.
12. Yoon BS, JH Moon, EK Jun, J Kim, I Maeng, JS Kim, JH Lee, CS Baik, A Kim, et al. (2010). Secretory profiles and wound healing effects of human amniotic fluid-derived mesenchy-mal stem cells. Stem Cells Dev 19:887-902.
13. Roubelakis MG, KI Pappa, V Bitsika, D Zagoura, A Vlahou, HA Papadaki, A Antsaklis and NP Anagnou. (2007). Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev 16:931-952.
14. Trohatou O, NP Anagnou and MG Roubelakis. (2013). Human amniotic fluid stem cells as an attractive tool for clinical applications. Curr Stem Cell Res Ther 8:125-132.
15. Cao DP, YN Zheng, LP Qin, T Han, H Zhang, K Rahman and QY Zhang. (2008). Curculigo orchioides, a traditional Chinese medicinal plant, prevents bone loss in ovariecto-mized rats. Maturitas 59:373-380.
16. Wang Y, L Zhao, J Xu, Y Nie, Y Guo, Y Tong, L Qin and Q Zhang. (2012). Curculigoside isolated from Curculigo orch-ioides prevents hydrogen peroxide-induced dysfunction and oxidative damage in calvarial osteoblasts. Acta Biochim Biophys Sin (Shanghai) 44:431-441.
17. Ma C, J Zhang, J Fu, L Cheng, G Zhao and Y Gu. (2011). Up-regulation of VEGF by MC3T3-E1 cells treated with curcu-ligoside. Phytother Res 25:922-926.
18. Ryoo HM, MH Lee and YJ Kim. (2006). Critical molecular switches involved in BMP-2-induced osteogenic differentiation of mesenchymal cells. Gene 366:51-57.
19. Lian JB, GS Stein, A Javed, AJ van Wijnen, JL Stein, M Montecino, MQ Hassan, T Gaur, CJ Lengner and DW Young. (2006). Networks and hubs for the transcriptional control of osteoblastogenesis. Rev Endocr Metab Disord 7:1-16.
20. Shen Q, D Zeng, Y Zhou, L Xia, Y Zhao, G Qiao, L Xu, Y Liu, Z Zhu and X Jiang. (2013). Curculigoside promotes osteo-genic differentiation of bone marrow stromal cells from ovariectomized rats. J Pharm Pharmacol 65:1005-1013.
21. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
22. Boyce BF and L Xing. (2008). Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473:139-146.
23. Huang W, S Yang, J Shao and YP Li. (2007). Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci 12:3068-3092.
24. Luo Q, Q Kang, W Si, W Jiang, JK Park, Y Peng, X Li, HH Luu, J Luo, et al. (2004). Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem 279:55958-55968.
25. Zhang JF, G Li, CY Chan, CL Meng, MC Lin, YC Chen, ML He, PC Leung and HF Kung. (2010). Flavonoids of Herba Epimedii regulate osteogenesis of human mesenchymal stem cells through BMP and Wnt/beta-catenin signaling pathway. Mol Cell Endocrinol 314:70-74.
26. Zhang JF, G Li, CL Meng, Q Dong, CY Chan, ML He, PC Leung, YO Zhang and HF Kung. (2009). Total flavonoids of Herba Epimedii improves osteogenesis and inhibits osteo-clastogenesis of human mesenchymal stem cells. Phytome-dicine 16:521-529.
27. Hadjidakis DJ and II Androulakis. (2006). Bone remodeling. Ann N Y Acad Sci 1092:385-396.
28. Kular J, J Tickner, SM Chim and J Xu. (2012). An overview of the regulation of bone remodelling at the cellular level. Clin Biochem 45:863-873.
29. Day TF, X Guo, L Garrett-Beal and Y Yang. (2005). Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8:739-750.
30. Hu H, MJ Hilton, X Tu, K Yu, DM Ornitz and F Long. (2005). Sequential roles of Hedgehog and Wnt signaling in osteo-blast development. Development 132:49-60.
31. Westendorf JJ, RA Kahler and TM Schroeder. (2004). Wnt signaling in osteoblasts and bone diseases. Gene 341:19-39.
32. Glass DA, 2nd, P Bialek, JD Ahn, M Starbuck, MS Patel, H Clevers, MM Taketo, F Long, AP McMahon, RA Lang and G Karsenty. (2005). Canonical Wnt signaling in differentiated os-teoblasts controls osteoclast differentiation. Dev Cell 8:751-764.
33. Bain G, T Muller, X Wang and J Papkoff. (2003). Activated beta-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduc-tion. Biochem Biophys Res Commun 301:84-91.
34. Rawadi G, B Vayssiere, F Dunn, R Baron and S RomanRoman. (2003). BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 18:1842-1853.
35. Hill TP, D Spater, MM Taketo, W Birchmeier and C Hartmann. (2005). Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 8:727-738.
36. Holmen SL, CR Zylstra, A Mukherjee, RE Sigler, MC Fau-gere, ML Bouxsein, L Deng, TL Clemens and BO Williams. (2005). Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 280:21162-21168.
37. Shtutman M, J Zhurinsky, I Simcha, C Albanese, M D'Amico, R Pestell and A Ben-Ze'ev. (1999). The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96:5522-5527.
38. Hamidouche Z, E Hay, P Vaudin, P Charbord, R Schule, PJ Marie and O Fromigue. (2008). FHL2 mediates dexametha-sone-induced mesenchymal cell differentiation into osteo-blasts by activating Wnt/beta-catenin signaling-dependent Runx2 expression. FASEB J 22:3813-3822.
39. Gaur T, CJ Lengner, H Hovhannisyan, RA Bhat, PV Bodine, BS Komm, A Javed, AJ van Wijnen, JL Stein, GS Stein and JB Lian. (2005). Canonical WNT signaling promotes osteogen-esis by directly stimulating Runx2 gene expression. J Biol Chem 280:33132-33140.
40. Teede HJ. (2003). The menopause and HRT. Hormone replacement therapy, cardiovascular and cerebrovascular disease. Best Pract Res Clin Endocrinol Metab 17:73-90.
41. Arum SM. (2008). New developments surrounding the safety of bisphosphonates. Curr Opin Endocrinol Diabetes Obes 15:508-513.
42. Li D, S Isherwood, A Motz, R Zang, ST Yang, J Wang and X Wang. (2013). Cell-based screening of traditional chinese medicines for proliferation enhancers of mouse embryonic stem cells. Biotechnol Prog 29:738-744.
43. Li D, R Zang, ST Yang, J Wang and X Wang. (2013). Cell-based high-throughput proliferation and cytotoxicity assays for screening traditional Chinese herbal medicines. Process Biochem 48:517-524.